Floatz logo

Recombinant Ephb4-Hsa Fusion Protein

Prostate Carcinoma Metastatic in the Bone

Northwestern Universityprotein_peptidePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

252 Active assets in the Prostate Carcinoma Metastatic in the Bone cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Ephb4-Hsa Fusion Protein is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
infiltrating bladder urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →